Genmab A/S

GNMSF ·Healthcare, Drug Manufacturers - General, Denmark
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023
Assets
Cash & Equivalents $1.72B $1.38B $2.20B
Accounts Receivable $1.13B $930.0M $743.0M
Inventory $18.0M $9.0M $8.0M
Total Current Assets $2.89B $3.90B $4.91B
Property, Plant & Equipment — — —
Goodwill $355.0M $355.0M $0
Intangible Assets (Excl. Goodwill) — — —
Total Assets $12.87B $6.41B $5.23B
Liabilities
Accounts Payable $145.0M $90.0M $49.0M
Total Current Liabilities $1.43B $744.0M $368.0M
Long-Term Debt $5.00B $0 $0
Total Liabilities $7.03B $1.28B $545.0M
Stockholders' Equity
Retained Earnings $4.10B $3.39B $2.74B
Total Stockholders' Equity $5.85B $5.14B $4.69B